Reported 8 months ago
SingLion's Chairman Tsai Cheng-hsien expressed excitement as the 'Dual Regulation of Regenerative Medicine' passed, leading academia and industry into the exosome field. SingLion leverages 25 years of regenerative medicine experience to introduce the Exosome Foundry global R&D model, merging the successful foundry model of TSMC and NVIDIA's AI Foundry into clinical healthcare. Through AI analysis, they aim to create next-gen exosome therapies and applications for various industries, synchronizing with the world for advancements. SingLion unveiled new exosome products including cord blood exosomes, PRE platelet exosomes, and mesenchymal stem cell exosomes, with collaborations for products like stem cell exosome masks. The Exosome Foundry is poised to maximize exosome applications through friendly regulations and high-quality preparations, revolutionizing diverse industries and medical specialties to elevate Taiwan's exosome sector into a global powerhouse. SingLion is expanding revenue and production capacity for exosomes and CRDMO processes, with a subsidiary planning to list on Taipei Exchange by 2025 and actively developing new exosome drugs like ExoTear for dry eye treatment, endorsed by the Center for Drug Evaluation.
Source: YAHOO